BRADFORD PATRICIA A purchased $12K of PHIO
BRADFORD PATRICIA A purchased 12,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.03 on 2026-09-15.
How this was made
The 30-second read
Why it matters
The transaction is small and unlikely to move the stock significantly, but it adds a data point for monitoring insider sentiment.
Market read
A modest insider purchase with limited immediate trading relevance; useful for longer‑term sentiment tracking.
What to watch
Potential upcoming clinical data or regulatory events could make the insider's timing more meaningful.
Background
Form 4 filings disclose insider transactions; directors buying shares can be viewed as confidence signals.
Ticker impact
Director Patricia Bradford purchased 12,000 PHIO shares at $1.03, increasing her holding to 57,651 shares.
Minor upward pressure, likely negligible price movement.
The purchase is modest in dollar terms (~$12k) and represents a routine insider transaction rather than a strategic stake increase.
Market effects
Minimal effect on the biotech sector; insider activity is typical for small‑cap pharma.
No regional impact beyond the company's own stock.
Limited relevance; only PHIO investors may note the buy.
Counterpoint
The purchase may be a routine portfolio rebalancing, not a strong endorsement.
Key entities
- CompanyPhio Pharmaceuticals Corp.
Biotech firm listed on Nasdaq under ticker PHIO.
- IndividualPatricia Bradford
Director of Phio Pharmaceuticals who executed the purchase.
